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The skin is an important barrier between the external envi-
ronment and our internal environment. It is exposed to 
chemical and physiological factors, changes in temperature, 
UV-irradiation from the sun and it is under constant attack 
from microbes and small agents. The skin is not only involved 
in heat regulation and one of its major roles is inhibiting patho-
gens from entering our tissues. The immune system plays a 
crucial role in the defenses, where both the innate and adap-
tive immune system are involved. When a pathogen infects the 
body, members in the first line of defense, which include neu-
trophils and antimicrobial peptides try to eliminate the patho-
gen. If this is not enough to eradicate the infection, other cells 
are called to the scene, the lymphocytes. Dendritic cells (DCs) 
in the tissues take up the pathogen and migrate to the lymph 
nodes draining the site of invasion. The DCs cut the pathogen 
into small pieces (antigens) and show antigens from the patho-
gen to T cells in the lymph nodes. If the T cells are activated, 
they can migrate to the site of infection.
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The skin is a vital organ that plays a crucial role in defending us 
from pathogens. Multiple players from the innate and adaptive 
immune system are involved, such as neutrophils, dendritic 
cells, lymphocytes and antimicrobial peptides. Chronic 
inflammatory skin diseases can be mediated by inflammatory T 
cells and their interactions with other cells in the skin. vitamin D 
is generated in the skin upon sun exposure and has a variety of 
effects. vitamin D and its analogs have been used with success 
in treating mild to moderate T cell-mediated skin diseases, but 
how they mediate the beneficial effects is not well understood. 
in the recent years, emerging evidence is rising that vitamin 
D analogs and its modulation on the immune system plays 
a major role. it has been shown that vitamin D analogs can 
induce the generation of regulatory T cells, which are able to 
suppress proliferation and alter the function of inflammatory 
T cells. This may help explain the therapeutic effects that are 
observed and at the same time give hope that in combination 
with other therapy or used alone, vitamin D analogs may be 
helpful when treating more severe forms of the diseases.
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Recirculation and Trafficking of Lymphocytes 
to Tissues
Lymphocytes circulate between blood, lymph nodes and tissues 
and back to the blood, and this recirculation is important both 
for immune surveillance as well as for cells responding to infec-
tions. The idea that cells recirculate was put forward when it was 
observed that there was a rapid turnover of T cells in the blood. 
It was suggested that lymphocytes migrate from the blood ves-
sels into tissues and return to lymphoid tissues through the affer-
ent lymph. By labeling lymphocytes from the thoracic duct of 
rats with 32P or 51Cr and injecting them back into the blood of 
the animal, it was demonstrated that these lymphocytes could 
be recovered in large amounts in the thoracic duct or intestinal 
lymph.1,2 Further experiments showed that this mechanism is 
quite selective and T cells migrated preferentially to the tissue of 
their origin.3 The observation that T cells preferentially migrate 
back to the tissue of origin or where the antigen came from was 
an important step towards understanding how recirculation 
occurs. This is an organized and efficient system that guides the 
T cells where they are needed the most at a particular time-point.
The interactions between T cells and the endothelium is a 
regulated process involving three or more sequential steps, start-
ing with initial contact between lymphocytes and the endothe-
lium to stable attachment and resulting in T cells infiltrating the 
tissue, where multiple receptors and ligands are involved. The ini-
tial tethering to the vascular endothelium is mediated by selectins 
and integrins, which enables the T cells to slow down, roll along 
the endothelium and sample the chemokines that are presented 
by the endothelial cells. Chemokines are small proteins that are 
presented by endothelial cells on the luminal surface and upon 
binding to T cells they trigger activation of integrins and increase 
affinity, which results in T cell arrest on the endothelial wall. 
If appropriate chemokines are present, the T cells attach more 
firmly to the endothelium. This leads eventually to transendothe-
lial migration of the T cells into the underlying tissue where the 
lymphocytes are guided further by chemokines and other che-
moattractants to find their specific location.4 Different selectins, 
chemokines and integrins are important for the infiltration into 
different tissues thus, lymphocytes have diverse combinations 
of these receptors. This generates specificity where the specific 
combination of receptors that is needed for T cell migration into 
lymph nodes is different from those needed to access tissues and 
the tissues themselves have their own specific combination.4
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found in serum of patients with skin diseases where T cells play 
an important role such as psoriasis and atopic dermatitis.17
Antimicrobial peptides also play an important role in defend-
ing the skin. Initial it was believed that these peptides were the 
skin’s antibiotics whose only function was to kill microbes.18 It 
is now clear that their function goes beyond that. In skin, many 
cell types can produce these peptides, including keratinocytes 
and mast cells. The two main types of antimicrobial peptides 
are cathelicidins and beta-defensins. The only known cathelici-
din in humans is LL-37 (reviewed in ref. 18).
Immunological Effects of Vitamin D
Vitamin D
3 
is generated in the skin after exposure to UVB-rays 
from the sun where it is converted to its active form, 1,25(OH)
2
D
3
, 
through an enzymatic pathway.19 When UVB-rays from the sun 
hit the skin, 7-dehydrocholesterol is converted to pre-vitamin D3, 
which isomerizes quickly to a more stable vitamin D3. Vitamin D
3 
is converted to 25-hydroxyvitamin D
3 
(25(OH)D) by 25-hydroxy-
lases, which are enzymes that are a part of the cytochrome P450 
family. 25(OH)D
3 
is a circulating metabolite that is converted to 
the active form, 1,25-dihydroxyvitamin D
3 
(1,25(OH)
2
D
3
), by 
1alpha-hydroxylase enzymes (Fig. 1).20 The conversion of vitamin 
D
3 
into its active form occurs mainly in the liver and kidneys, how-
ever, it has been shown that several other cell types are also capable 
of this conversion, including keratinocytes,21 macrophages22 and 
DCs,20 which can all be present in the skin.
The biological effects of 1,25(OH)
2
D
3 
are mediated through 
the vitamin D receptor (VDR), which is a member of the super-
family of nuclear hormone receptors. The binding of 1,25(OH)
2
D
3
 
to VDR leads to a conformational change in the VDR, and it binds 
to the retinoic X receptor (RXR), forming a heterodimer. This het-
erodimer translocates to the nucleus, where it can bind to a vitamin 
D response element and can either promote or prevent transcription 
of vitamin D-responsive genes in target cells.20 VDR is expressed in 
a variety of cells, such as bone, skin, intestines, kidneys and cells of 
the immune system. In skin, vitamin D
3 
is produced by keratino-
cytes and is known to regulate keratinocyte differentiation, inhibit 
keratinocyte proliferation and induce terminal differentiation of 
the keratinocytes.23 1,25(OH)
2
D
3
 has also been shown to have a 
variety of immunomodulatory effects, but VDR is expressed by 
activated B and T cells (both CD4+ and CD8+ T cells), mono-
cytes, DCs and macrophages (reviewed in ref. 24). VDR expres-
sion is increased in activated T cells and binding of 1,25(OH)
2
D
3
 
decreases the production of IFNgamma, IL-2, IL-17 and IL-22 
from the T cells, while increasing the production of IL-4.24 This 
prevents or diminishes the expansion of proinflammatory Th1 and 
Th17 cells, which are major groups of inflammatory T cells. Thus, 
human T cells are affected directly by 1,25(OH)
2
D
3
.24,25
Dendritic Cells are important Regulators  
of T Cell Trafficking
One of the most important roles of DCs is the uptake of antigens 
and foreign substances and presenting them to T cells. The tissues 
where the DCs are derived from are important. Intestinal DCs 
Naïve lymphocytes are not very efficient in mediating 
immune responses and are activated by DCs within secondary 
lymphoid tissues, such as lymph nodes and spleen. In lymph 
nodes draining the skin, T cells are activated by DCs that have 
migrated from the skin and upon activation, these T cells start 
to express specific homing molecules, which enable them to 
leave the blood circulation and infiltrate the skin. The mol-
ecules that are known to be important for the migration into 
the skin include the adhesion molecule cutaneous lymphocyte-
associated antigen (CLA), which binds to E-selectin on the 
vascular endothelial cells, and the chemokine receptor, CCR4, 
which binds to “chemokine thymus and activation-regulated 
chemokine” (TARC/CCL17).5-8 Within the skin the T cells can 
respond to chemokines such as macrophage-derived chemokine 
(MDC/CCL22),9 which can be secreted by various cell types 
and the “epithelial cutaneous T cell-attracting chemokine” 
(CTACK/CCL27), which is primarily expressed by keratino-
cytes in the skin and attracts T cells expressing CCR10.10-12 
Increased expression of CCL17 and CCL27 is observed in 
inflamed skin12,13 and blocking CCL17 and CCL22 (the known 
ligands for CCR4), significantly reduced the numbers of T 
cells in inflamed ears in a mouse model of contact hypersen-
sitivity.14 In contrast, blocking CCL27 alone did not appear 
to reduce the recruitment of T cells into the skin.15 CCL28 
(“mucosa-associated epithelial chemokine”/MEC) is also a 
ligand for CCR10 and increased levels of CCL28 are found in 
the mucosa.16 However, elevated levels of CCL28 have also been 
Figure 1. The generation of 1,25(OH)2D3. when UvB-rays from the sun 
hit the skin, 7-dehydrocholesterol is converted to pre-vitamin D3, which 
isomerizes quickly to a more stable vitamin D3. vitamin D3 is rapidly 
converted to 25-hydroxyvitamin D (25(OH)D) by 25-hydroxylases, which 
are enzymes from the cytochrome P450 family. 25(OH)D is a circulating 
metabolite that is converted to the active form, 1,25(OH)2D3, by 1 alpha-
hydroxylase enzymes.
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antimicrobial peptide LL-37 and DNA binding to the Toll-like 
receptor 9 (TLR 9). pDCs do not normally respond to self-DNA 
but LL-37 was found to convert self-nucleic acid into a potent trig-
ger of pDC activation by forming a complex with self-RNA and 
self-DNA. This triggers the activation of the pDCs through TLR9. 
The LL-37-self-DNA complexes signaled through the TLR9 and 
induced the release of IFNalpha from pDCs, which subsequently 
generated a T-cell response.40 LL-37 is normally not expressed in 
large amounts in healthy skin but it is overexpressed by keratino-
cytes in psoriatic skin. This could help explain why pDCs and 
subsequently T cells in psoriatic skin, can be chronically activated.
AD is a chronic inflammatory skin disease, where genetic, envi-
ronmental and immunologic factors play a role in the pathogenesis 
of the disease. DCs also play a crucial role in the initiation and 
amplification of the immune response. The skin barrier in AD is 
impaired and this enables allergens and microbial antigens to come 
into close contact with DCs in the skin. Cross-linking of allergen-
specific IgE molecules on skin DCs or binding of bacterial prod-
ucts induces a cascade of events resulting in increased numbers of 
activated circulating CD4+ and CD8+ T cells. Increased numbers 
of CD4+ T cells are also found in the dermis of patients with AD. 
In contrast to psoriasis, the T cells that are believed to initiate the 
acute phase of AD produce mainly IL-4, IL-5, IL-13 and IL-31.41,42 
CCR8 (the receptor for CCL1) is implicated in the migration of 
T cells into the skin of patients with AD,43 and increased CCL1, 
CCL13, CCL17 and CCL18 expression was observed in patients 
with chronic AD compared with those with psoriasis. Furthermore, 
stronger expression of CCL1, CCL3, CCL4 and CCL11 mRNA 
was detected in patients with acute AD compared with chronic 
AD.13
It has been demonstrated that both CCL27 is strongly expressed 
in lesional skin of patients with AD and psoriasis.10 Furthermore, 
increased levels of CCL28 is found in serum of patients with AD 
and psoriasis.17 CCL27 and CCL28 are both ligands for CCR10+ 
T cells, which enables the T cells to migrate from the dermal to the 
keratinocytes in the epidermal layers of the skin.
Vitamin D as Treatment for Skin Diseases
Vitamin D
3 
derivatives and analogs are commonly used to treat 
mild to moderatecases of skin diseases such as psoriasis and atopic 
dermatitis.44 How they mediate their beneficial effects is not fully 
understood. Vitamin D analogs can be beneficial by balancing 
the hyperproliferation of the keratinocytes, and in recent years 
the role of vitamin D analogs in regulating the immune system 
is becoming more evident. Incorporating vitamin D with other 
treatments may also prove to be a candidate for a more effec-
tive targeted combination therapy in skin diseases although that 
needs further investigations.45
Vitamin D creams and oral supplements. Vitamin D
3 
oint-
ments and creams have been used for a long time as a treatment 
for psoriasis and shown beneficial effects in mild to moderate 
cases of the disease.45,46 Vitamin D can be obtained from the diet 
and by UV-induced synthesis in the skin as previously described. 
Food, however, is not a rich source of vitamin D but vitamin D 
can also be taken as a supplement.
are derived from lymph nodes that drain the intestines, and when 
DCs from these lymph nodes were used to activate T cells, the 
expression of gut-homing receptors was induced on the respond-
ing T cells.26,27 It was proposed that intestinal DCs are special-
ized in the induction of T cells that preferentially migrate to the 
gut. Specificity of DCs from these lymph nodes can, however, be 
altered and under different environmental conditions these DCs 
can induce the expression of skin-homing receptors on T cells.28,29 
It is, therefore, not only the DCs but the local microenvironment 
that is crucial for the expression of homing receptors.
External environmental factors, including active metabolites 
of vitamins, have been shown to have significant effects on the 
homing of T cells. Vitamin A is mainly obtained through the diet, 
and it can be taken up, transported to the draining lymph nodes 
and processed by the local DCs and stromal cells.30-32 Vitamin 
A is metabolized in two steps to retinoic acid (RA), which is the 
most active from of the vitamin.20 Both DCs and stromal cells 
from the intestines had the enzymes needed to convert vitamin 
A to RA and were more effective than DCs from the peripheral 
lymph nodes (such as skin draining lymph nodes) at inducing 
the expression of the gut-homing receptors alpha4beta7 integrin 
and CCR9 on T cells.30-32 In contrast, the stromal cells in lymph 
nodes draining the skin do not appear to have these enzymes.
Vitamin D has been associated with localization of T cells 
within the skin. DCs express the enzymes and are able to convert 
vitamin D
3 
to 1,25(OH)
2
D
3
.33 When 1,25(OH)
2
D
3
 was pres-
ent during activation, the expression of CCR10 was induced on 
the responding T cells,33 which enables the T cells to migrate 
to the keratinocytes in the epidermal layers of the skin. The T 
cells themselves had one the of enzymes needed and were able 
to convert 25(OH)D
3 
to 1,25(OH)
2
D
3
 and their expression of 
CCR10 was increased. These results strengthen the role of micro-
environmental factors in regulating T cell responses and thereby 
affecting immune responses.
T Cell Mediated Skin Diseases
Psoriasis and atopic dermatitis (AD) are chronic inflammatory 
skin diseases, where an important factor in the pathogenesis of the 
disease is increased infiltration of T cells into the skin. Psoriasis 
is characterized by raised, well-demarcated, erythematous plaques 
with silvery scales. In psoriatic lesions, keratinocytes hyperprolifer-
ate resulting in thickening of the epidermis with elongated rete 
ridges.34 There is increased infiltration of cells of the immune 
system into the dermal and epidermal layers of the skin. The 
inflammatory infiltrate consists mainly of DCs, macrophages and 
CD4+ T cells in the dermis and neutrophils and CD8+ T cells are 
dominating in the epidermis.34 In psoriasis, the CD4+ T cells in 
lesional skin are mostly of the Th1 and Th17 type, which produce 
IFNγ and IL-17,35-37 and recently a new T cell subpopulation has 
been described to be overexpressed in psoriasis, the Th22 cells.37,38 
Plasmacytoid DCs (pDCs) are present in early psoriatic lesions, 
where they can become activated and secrete IFNa.39 In a xenograft 
model of human psoriasis, blocking IFNa signaling or inhibiting 
the ability of pDCs to produce IFNa prevented the development 
of psoriasis.39 pDCs can be activated through complexes of the 
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It may be contradictory that topical 1,25(OH)
2
D
3
 applications 
are beneficial in psoriasis as such treatment has been reported to 
irritate the skin.59 One could expect that it would by difficult to 
use vitamin D analogs when treating skin diseases, yet, vitamin D
3 
analogs have been used to treat psoriasis for a long time success-
fully. Also, both vitamin D
3 
analogs and UVB-treatment, which 
are common effective treatments in psoriasis, increase the produc-
tion of LL-37 from keratinocytes,48 and this should make psoriasis 
worse as it activates the pDCs,39,40 followed by increased produc-
tion of IFNalpha. However, vitamin D
3 
analogs have been found 
to decrease inflammation in skin48 and in part reverse the changes 
observed within lesional skin. The reason for this is not clear, but 
it suggests that the proposed pathogenic role of LL-37 in skin dis-
eases such as psoriasis, needs further investigation.
Vitamin D induces the generation of T regulatory cells in the 
skin. The important role of DCs in T cell activation is highly rel-
evant for T cell mediated skin diseases. Targeted immunotherapy 
and other treatments have been shown to reduce the numbers of 
DCs in patients with psoriasis with beneficial effects indicating an 
important role of these cells in the pathogenesis of psoriasis.
1,25(OH)
2
D
3
 is known to have immunosuppressive effects as 
previously described and one of their effects is to inhibit matura-
tion of DCs.60-62 In the presence of 1,25(OH)
2
D
3
, the expression 
of co-stimulatory molecules and maturation markers is decreased 
on DCs (reviewed in ref. 24) making them less effective as stimu-
lators of T cells. Furthermore, 1,25(OH)
2
D
3
 has also been shown 
to induce the generation of regulatory T cells.63-65 Several different 
types of regulatory T cells have been described, which have the 
capacity to inhibit a diversity of immune responses and maintain 
immunologic tolerance in the periphery.66 Many cell types are 
known to be able to inhibit immune responses by production of 
anti-inflammatory cytokines, but a lot of attention has been given 
to T cells called regulatory T cells. These regulatory T cells are 
of specific interest in the context of T cell mediated skin diseases 
because of their ability to suppress proliferation and expansion of 
antigen-specific T cells. Several regulatory T cells exist, but one the 
most studied cells today are CD4+ T cells that are CD25+CD127low 
expressing cells. These cells are thought to play an important 
role in maintaining peripheral tolerance and inhibiting immune 
responses to self antigens.
It was shown that 1,25(OH)
2
D
3
 selectively induced myeloid 
DCs to become tolerogenic DCs, which were able to suppress T cell 
activity and decrease their production of IFNg.64 In contrast, these 
effects were not seen for the pDCs. But, as 1,25(OH)
2
D
3
 is known 
to prevent maturation of DCs, treatment with 1,25(OH)
2
D
3 
could 
prevent the maturation of the pDCs, making them very weak acti-
vators of T cells. Most in vivo data on the effects of 1,25(OH)
2
D
3
 
on T regulatory cells comes from animal studies. In mice, it was 
demonstrated that topically applied 1,25(OH)
2
D
3
 enhanced the 
suppressive capacity of CD4+CD25+ cells from the draining lymph 
nodes.67,68 The vitamin D analog, TX527 induced the generation 
of CD4+ CD25highCD127low regulatory T cells with functional 
capacity to suppress activation and proliferation of effector T cells. 
Furthermore, these regulatory T cells had increased expression 
of homing molecules making them capable of entering inflamed 
sites, where they can suppress the inflammatory T cells.69 It 
The active metabolite, 1,25(OH)
2
D
3
 is known to induce kera-
tinocyte to produce more of the antimicrobial peptide LL-37 and 
its antimicrobial activity is increased in vitro.47 Furthermore, psori-
atic patients treated topically with 1,25(OH)
2
D
3
 (calcipotriol) had 
increased levels of LL-37 levels in lesional and non-lesional skin.48 
Other studies have also shown that topical treatment with vitamin 
D analogues enhanced the upregulation of the antimicrobial pro-
tein hCAP18/LL-37,49 which was also rapidly upregulated upon 
skin injury,49 further demonstrating 1,25(OH)
2
D
3
 as a regulator of 
LL-37 production. Increased levels of the LL-37 protein have been 
detected in skin biopsies of patients with AD after supplementa-
tion with oral vitamin D.50 Patients with AD have lower levels of 
LL-37 compared to patients with psoriasis51 and this has raised the 
hope that by increasing the vitamin D
3 
metabolism or elevating 
vitamin D
3 
serum levels, it may be possible to restore an effective 
barrier in the skin of patients with AD. Not much is known about 
the effects of vitamin D on the production and secretion of either 
CCL27 or CCL28.
Ultraviolet B (UVB) irradiation and vitamin D production. 
Treatment with UVB irradiation is a common treatment and is 
known to have therapeutic effects when treating psoriasis and to 
some extent AD. UVB affects the skin directly by inducing the 
differentiation of keratinocytes.52 It has also been postulated that 
the beneficial effects of UVB are in part due to their effects on 
T cells, such as decreased expression of skin homing molecules,53 
decreased production of pro-inflammatory cytokines,54,55 and/
or apoptosis of T cells.56 The beneficial effects of UVB irradia-
tion may also be in part due to increased vitamin D production. 
Several studies have demonstrated that keratinocytes are fully 
functional at generating vitamin D during UVB irradiation. 
Cultured keratinocytes were shown to generate both vitamin D
3 
and 1,25(OH)
2
D
3 
(calcitriol) from 7-dehydrocholesterol after 
UVB-irradiation and LL-37 production was also increased.57 
Using a different model (a skin-equivalent model), it was also 
demonstrated that during irradiation with UVB, previtamin D
3 
is generated from 7-dehydrocholesterol, which is converted to 
vitamin D3, followed by the formation of 25(OH)D
3 
(calcidiol) 
and finally the generation 1,25(OH)
2
D
3
 (calcitriol), In contrast, 
non-irradiated cultures and irradiated cultures without keratino-
cytes did not produce calcitriol. The amount of calcitriol that 
was generated was not only dependent on the concentration 
of 7-dehydrocholesterol but also on the UVB doses used. The 
results indicate that in the presence of physiologic concentrations 
of 7-dehydrocholesterol, keratinocytes may be a source of biologi-
cally active 1,25(OH)
2
D
3
 when irradiated with therapeutic doses 
of ultraviolet B.21
Another study showed that at onset of disease, patients with 
psoriasis or AD had vitamin D levels that could indicate insuf-
ficiency of vitamin D, but treatment with narrowband UVB 
irradiation significantly increased the levels in the serum of 
these individuals. The disease severity score (Psoriasis Area 
and Severity Index) improved significantly but no correlation 
was found to the increase of serum calcidiol. After narrowband 
UVB treatment, the production of the antimicrobial peptide 
LL-37 was increased, while human beta-defensin 2 expression 
was decreased in both psoriatic and AD lesions.58
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has also been shown that immunization through 
1,25(OH)
2
D
3
 treated skin induced the generation of 
CD4+CD25+ regulatory T cells, which were able to 
prevent the proliferation of antigen-specific CD8+ T 
cells and their production of IFNg.67 When the effects 
of topical application of 1,25(OH)
2
D
3
 were compared 
with those of UVB irradiation, CD4+ cells from skin-
draining lymph nodes of either 1,25(OH)
2
D
3
-treated 
or UVB-irradiated mice could suppress antigen-spe-
cific immune responses when transferred adoptively 
into naive mice. Also, these cells had increased capac-
ity to suppress immune responses in both in vitro and 
in vivo assay systems.68
Thus, vitamin D analogs may help the immune 
system in targeting and inhibiting specifically the 
function and proliferation of inflammatory T cells at 
inflamed sites, such as the skin (Fig. 2).
Conclusion
T cell mediated skin diseases affect millions of people 
around the globe. They can be very uncomfortable to 
those affected and have been reported to reduce the 
quality of life of those affected.70 Treatments are gener-
ally rather unspecific and do not always target the skin 
specifically. More and more is being done in develop-
ing more specific treatments that target the skin as an 
organ. Combination therapy also gives hope that less 
concentrations can be used of each of the drugs mak-
ing them safer to use. Vitamin D and its analogs may 
prove to be ideal candidates for combination treat-
ments and as we learn more about them and how they 
work, we can design the ideal combination to use that 
is effective but safe.
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Figure 2. Hypothesis: Benefits of topical application of 1,25D3. when DCs are matur-
ing in the presence of 1,25(OH)2D3 (1,25D3), they capability to fully mature is decreased 
and they become less efficient at taking up antigen and activating T cells. instead they 
become tolerogenic and induce the generation of regulatory T cells, which suppress 
the proliferation of effector T cells and alter their cytokine production. These regula-
tory T cells have increased expression of homing receptors enabling them to enter 
sites of inflammation. The results are that the effector T cells (inflammatory cells) at 
inflamed sites are not effective at proliferating or producing inflammatory cytokines 
(decreased production of iL-17, iL-22 and iFNgamma). There is a decrease in the inflam-
matory response and the disease resolves slowly.
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